{"id":746981,"date":"2023-04-12T08:19:31","date_gmt":"2023-04-12T12:19:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/"},"modified":"2023-04-12T08:19:31","modified_gmt":"2023-04-12T12:19:31","slug":"day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/","title":{"rendered":"Day One Announces Upcoming Presentation at 19th European Association of  Dermato-Oncology (EADO) Congress"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BRISBANE, Calif., April  12, 2023  (GLOBE NEWSWIRE) &#8212; Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced an upcoming poster presentation at the 19<sup>th<\/sup> European Association of Dermato-Oncology (EADO) Congress being held from April 20-22, 2023 in Rome, Italy.<\/p>\n<p>Details are as follows:<\/p>\n<p>\n        <u>Title:<\/u> Clinical Activity of the Type II pan-RAF Inhibitor Tovorafenib in BRAF-fusion Melanoma<br \/><u>Format:<\/u> Poster Presentation <br \/><u>Poster Number:<\/u> 174<br \/><u>Session:<\/u> Guided Poster Tour 2<br \/><u>Category:<\/u> Melanoma: Experimental research, surgery and systemic treatment <br \/><u>Date and Time:<\/u> Thursday, April 20; 8:45 \u2013 9:30 AM ET<\/p>\n<p>\n        <strong>About Tovorafenib <\/strong><br \/>\n        <br \/>Tovorafenib is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in primary brain tumors or brain metastases of solid tumors. Tovorafenib has been studied in over 325 patients to date. Currently tovorafenib is under evaluation in a pivotal Phase 2 clinical trial (FIREFLY-1) among pediatric, adolescent and young adult patients with relapsed or progressive pLGG, which is an area of considerable unmet need with no approved therapies for the vast majority of patients. Tovorafenib is also being evaluated alone or as a combination therapy for adolescent and adult patient populations with recurrent or progressive solid tumors with MAPK pathway aberrations (FIRELIGHT-1).<\/p>\n<p>Tovorafenib has been granted Breakthrough Therapy and Rare Pediatric Disease designations by the U.S. Food and Drug Administration (FDA) for the treatment of patients with pLGG harboring an activating RAF alteration. Tovorafenib has also received Orphan Drug designation from the FDA for the treatment of malignant glioma, and from the European Commission (EC) for the treatment of glioma.<\/p>\n<p>\n        <strong>About Day One Biopharmaceuticals <\/strong><br \/>\n        <br \/>Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better. We put kids first and are developing targeted therapies that deliver to their needs. Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. The Company\u2019s name was inspired by the \u201cThe Day One Talk\u201d that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to re-envision cancer drug development and redefine what\u2019s possible for all people living with cancer\u2014regardless of age\u2014starting from Day One.<\/p>\n<p>Day One partners with leading clinical oncologists, families and scientists to identify, acquire and develop important emerging cancer treatments. The Company\u2019s lead product candidate, tovorafenib (DAY101), is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor. The Company\u2019s pipeline also includes pimasertib, an investigational, oral, highly-selective small molecule inhibitor of mitogen\u2010activated protein kinases 1 and 2 (MEK-1\/-2). Day One is based in Brisbane. For more information, please visit www.dayonebio.com or find the company on LinkedIn or Twitter.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking\u201d statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Day One\u2019s plans to develop cancer therapies, expectations from current clinical trials, the execution of the Phase 2 and Phase 3 clinical trial for tovorafenib as designed, any expectations about safety, efficacy, timing and ability to complete clinical trials, release data results and to obtain regulatory approvals for tovorafenib and other candidates in development, and the ability of tovorafenib to treat pLGG or related indications.<\/p>\n<p>Statements including words such as \u201cbelieve,\u201d \u201cplan,\u201d \u201ccontinue,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201cdevelop,\u201d \u201csignal,\u201d \u201cpotential,\u201d or \u201congoing\u201d and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements.<\/p>\n<p>Forward-looking statements are subject to risks and uncertainties that may cause Day One\u2019s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties in this press release and other risks set forth in our filings with the Securities and Exchange Commission, including Day One\u2019s ability to develop, obtain regulatory approval for or commercialize any product candidate, Day One\u2019s ability to protect intellectual property, the potential impact of global business or macroeconomic conditions, including as a result of the COVID-19 pandemic, inflation and rising interest rates and the sufficiency of Day One\u2019s cash, cash equivalents and investments to fund its operations. These forward-looking statements speak only as of the date hereof and Day One specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p>\n        <strong>DAY ONE MEDIA<\/strong><br \/>\n        <br \/>Laura Cooper, Head of Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kxxypctUPnvIH6IbSYvV54PYNLQcR--wEkiPVhJqsHlp4rFf_sfkAdoz1agMrD7VPB-F1tAGL1EsElHAJAWFxGQ3_ZkQR5wavs3fOavZ6aw=\" rel=\"nofollow noopener\" target=\"_blank\">media@DayOneBio.com<\/a><\/p>\n<p>\n        <strong>DAY ONE INVESTORS<\/strong><br \/>\n        <br \/>LifeSci Advisors, PJ Kelleher<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v8u0ysHmmPJyceyjIWiERu9nswoWi4Nh3U8agPwWhtNk2fNMs3pgK5L1Hp9_L5nC1vSA2aBRBdlTLeEJ7b6305WpDfpMdELK2538MqIYpPzbUAKH2gVbKfUugqNVL20Y\" rel=\"nofollow noopener\" target=\"_blank\"><u>pkelleher@lifesciadvisors.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjE4NiM1NTIxNjY2IzIyMDkxNjE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YTJkYjRhNTctNDgyOS00YjQyLThjMWItZGU0YzBlM2Y0YjdlLTEyMjA3MTQ=\/tiny\/Day-One-Biopharmaceuticals-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRISBANE, Calif., April 12, 2023 (GLOBE NEWSWIRE) &#8212; Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced an upcoming poster presentation at the 19th European Association of Dermato-Oncology (EADO) Congress being held from April 20-22, 2023 in Rome, Italy. Details are as follows: Title: Clinical Activity of the Type II pan-RAF Inhibitor Tovorafenib in BRAF-fusion MelanomaFormat: Poster Presentation Poster Number: 174Session: Guided Poster Tour 2Category: Melanoma: Experimental research, surgery and systemic treatment Date and Time: Thursday, April 20; 8:45 \u2013 9:30 AM ET About Tovorafenib Tovorafenib is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Day One Announces Upcoming Presentation at 19th European Association of  Dermato-Oncology (EADO) Congress&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-746981","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRISBANE, Calif., April 12, 2023 (GLOBE NEWSWIRE) &#8212; Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced an upcoming poster presentation at the 19th European Association of Dermato-Oncology (EADO) Congress being held from April 20-22, 2023 in Rome, Italy. Details are as follows: Title: Clinical Activity of the Type II pan-RAF Inhibitor Tovorafenib in BRAF-fusion MelanomaFormat: Poster Presentation Poster Number: 174Session: Guided Poster Tour 2Category: Melanoma: Experimental research, surgery and systemic treatment Date and Time: Thursday, April 20; 8:45 \u2013 9:30 AM ET About Tovorafenib Tovorafenib is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme &hellip; Continue reading &quot;Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-12T12:19:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjE4NiM1NTIxNjY2IzIyMDkxNjE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress\",\"datePublished\":\"2023-04-12T12:19:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\\\/\"},\"wordCount\":812,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNjE4NiM1NTIxNjY2IzIyMDkxNjE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\\\/\",\"name\":\"Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNjE4NiM1NTIxNjY2IzIyMDkxNjE=\",\"datePublished\":\"2023-04-12T12:19:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNjE4NiM1NTIxNjY2IzIyMDkxNjE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNjE4NiM1NTIxNjY2IzIyMDkxNjE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/","og_locale":"en_US","og_type":"article","og_title":"Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress - Market Newsdesk","og_description":"BRISBANE, Calif., April 12, 2023 (GLOBE NEWSWIRE) &#8212; Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced an upcoming poster presentation at the 19th European Association of Dermato-Oncology (EADO) Congress being held from April 20-22, 2023 in Rome, Italy. Details are as follows: Title: Clinical Activity of the Type II pan-RAF Inhibitor Tovorafenib in BRAF-fusion MelanomaFormat: Poster Presentation Poster Number: 174Session: Guided Poster Tour 2Category: Melanoma: Experimental research, surgery and systemic treatment Date and Time: Thursday, April 20; 8:45 \u2013 9:30 AM ET About Tovorafenib Tovorafenib is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme &hellip; Continue reading \"Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-12T12:19:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjE4NiM1NTIxNjY2IzIyMDkxNjE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress","datePublished":"2023-04-12T12:19:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/"},"wordCount":812,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjE4NiM1NTIxNjY2IzIyMDkxNjE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/","name":"Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjE4NiM1NTIxNjY2IzIyMDkxNjE=","datePublished":"2023-04-12T12:19:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjE4NiM1NTIxNjY2IzIyMDkxNjE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjE4NiM1NTIxNjY2IzIyMDkxNjE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/day-one-announces-upcoming-presentation-at-19th-european-association-of-dermato-oncology-eado-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=746981"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746981\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=746981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=746981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=746981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}